‘Friendly Breakup’: Sanofi And Regeneron Agree Equity Revamp

Pair Say Stock Move Will Not Hurt Their Drug Development Pact

26 May 2020

• By Sten Stovall

Sanofi to sell most of its Regeneron stake, with much of it being re-purchased by Regeneron, but both stressed the move would not hurt their long established and very profitable drug-development collaboration.

Sanofi selling Regeneron stake, Regeneron repurchasing $5bn of own shares. • Source: Shutterstock

In a mutually agreed set of stock transactions, Sanofi will offload most of its 20.6% stake in Regeneron Pharmaceuticals Inc. while the US pharma will buy much of it back as part of CEO Paul Hudson’s plan to generate cash and re-vamp the French drug maker. Both said the co-ordinated equity exercise would not hurt their successful and lucrative drug development partnership.

The two companies have had a research and marketing partnership since 2003, which led Sanofi to build up an equity...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Altimmune’s Phase IIb MASH Data Send Share Price Plunging

27 Jun 2025

• By Joseph Haas

Altimmune’s stock price did not recover on June 27, after a 57% dip the day before, despite efforts to position pemvidutide as both resolving MASH and offering weight loss.

Deal Watch: Novartis To Develop Cardiovascular Therapies With ProFound

27 Jun 2025

• By Joseph Haas, Sushmita Panda, Jung Won Shin, and Alaric DeArment

Plus deals involving BioCryst/Neopharmed Gentili, Sanofi/Kymera, Abion, Denovo/Chuang Yi, Carisma/OrthoCellix, Otsuka/Harbour Biomed, Aptose/Hanmi, Philochem/RayzeBio, Concentra/Elevation Oncology, and more.